NanoViricides Updates

By Ray BlancoPosted July 30, 2013

In our last update, we mentioned NanoViricides' application for FDA orphan drug status for its dengue drug, DengueCide. Successfully receiving this designation, which is designed to encourage development of rare and tropical disease therapies, would greatly speed DengueCide's commercialization ramp. This would not only be a boon for NanoViricides and its investors, but for dengue patients as well.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

ISCO Proves hpSCs’ Value in Animal Parkinson’s Study

By Patrick CoxPosted February 5, 2013

International Stem Cell Corporation is, of course, the company that developed and patented commercializable human parthenogenetic stem cell (hpSC) science. These stem cells, called either parthenogenic or parthenogenetic stem cells, come from the parthenotes in the female ova or their immature form, oocytes. The word oocyte, incidentally, is pronounced OH-a-site. Parthenotes, as you know, are cells that have shed one half of their DNA in readiness for fertilization. This doesn't mean that these gametes, ova and spermatazoa, have only one strand of the double helix, however. In these cells, both helices of the double helix are the same.

The Power of Technology

By Patrick CoxPosted September 8, 2009

Since I was working on Labor Day, I've decided to change the topic a bit. Specifically, I want to talk about a significant bit of technological history that just happened.

Echo Therapeutics Launches Onto Nasdaq, BioTime Insiders Buying Own Stock

By Patrick CoxPosted June 28, 2011

Many of the breakthroughs I'm talking about will have a direct and dramatic impact on your healthy life span, your “health span,” as well as your portfolio. There were many biotech breakthroughs this year...

Post-March Madness — Buy, Sell or Hold?

By Stephen PetranekPosted April 6, 2015

Biotech entered its own form of March madness, with prices dropping last month and lots of volatility. Does any of this look familiar? Yes. It looks a lot like this time last year.

Little-Known Biotech on Track to Make History

By Ray BlancoPosted April 22, 2019

Gene therapies and gene editing are grabbing all the headlines in biotech these days. But there are few companies tackling human health via interacting with our epigenetics…

Supreme Court Gene Ruling Has Silver Lining for BioTime

By Patrick CoxPosted June 18, 2013

Whenever the Supreme Court hands down a ruling on some company's patent claim to a gene, markets tend to react, as investors worry about possibly far-reaching consequences. This isn't, of course, surprising. The science behind gene patents is complicated. Biotech patent law is just as confusing, but is even more inscrutable because it is decided by humans, rather than nature. At stake are thousands of gene patents.

Login